NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: State University of Maringá
Conditions: Multiple Sclerosis
Interventions: Progressive Resistance Training, Stretching and Relaxation Activities
Countries: Brazil
This randomized controlled trial aims to investigate the effects of a supervised resistance training program on plasma levels of Brain-Derived Neurotrophic Factor (BDNF) and irisin in individuals diagnosed with multiple sclerosis (MS). The study will also examine secondary outcomes, including fatigue, quality of life, anxiety and depression symptoms, muscular strength, and functional capacity. Participants will be randomly assigned to either an intervention or control group in a 2:1 allocation ratio. The intervention group will undergo a 12-week supervised resistance training program, while the control group will maintain their usual care without engaging in any structured exercise regimen. The trial will be non-blinded and involve assessments at baseline and after the 12-week intervention period. Eligible participants must be adults (≥18 years), of any sex, with a confirmed diagnosis of MS by a neurologist, and currently undergoing disease-modifying therapy (DMT). Participants must not be engaged in any other structured physical exercise program, though symptom-management physiotherapy will be permitted. All participants should have sufficient mobility to complete the training sessions and assessments. Exclusion criteria include the inability to perform the physical training or functional tests due to severe mobility restrictions, lack of standard pharmacological treatment for MS, or concurrent participation in other structured exercise programs.
Sex: ALL
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Confirmed diagnosis of Multiple Sclerosis (MS) according to the 2017 McDonald Criteria * Expanded Disability Status Scale (EDSS) score between 1.0 and 6.0 * Age between 18 and 60 years * Medical clearance to engage in physical exercise * Ability to understand and provide written informed consent * Stable pharmacological treatment for MS for at least 3 months prior to enrollment * No MS relapses or corticosteroid use within 30 days before starting the intervention Exclusion Criteria: * Pregnancy or planning to become pregnant during the study period * Severe musculoskeletal conditions contraindicating exercise * Participation in another structured or systematic exercise program * Visual, cognitive, or communication impairments that may hinder participation * Use of orthopedic devices incompatible with the intervention protocols * Any other condition that, in the opinion of the research team, may interfere with participation or compromise data integrity
- Maringá, Paraná, Brazil